Vitura Health Limited (VIT.XA)
| Previous close | 0.0890 |
| Open | 0.0900 |
| Bid | 0.0000 x N/A |
| Ask | 0.0900 x N/A |
| Day's range | 0.0790 - 0.0900 |
| 52-week range | 0.0750 - 0.6000 |
| Volume | |
| Avg. volume | 266,277 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.18 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 20 Aug 2024 - 25 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Could The Market Be Wrong About Vitura Health Limited (ASX:VIT) Given Its Attractive Financial Prospects?
It is hard to get excited after looking at Vitura Health's (ASX:VIT) recent performance, when its stock has declined...
GlobeNewswireCronos Enters Australian Cannabis Market
TORONTO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) announced today that it is expanding distribution into the Australian market with its first shipment of cannabis flower to Vitura Health Limited (“Vitura”) (ASX: VIT). Cronos owns approximately 10% of the common shares of Vitura, formerly known as Cronos Australia, and will supply cannabis for Vitura. “Supplying the Australian market, which has grown significantly in the past three
GlobeNewswirePharmAla Files Audited Financials for Year Ending August 31, 2023
Highlights include Revenue Growth, Expansion of IP Licensing, and formation of Cortexa Joint VentureVANCOUVER, British Columbia, Dec. 29, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is pleased to file its audited financial statements for the year ended on August 31, 2023. Following is a short list of th
